AbbVie (ABBV) Pipeline Bolstered as FDA Approves Mavyret Label Expansion for Hepatitis C

AbbVie (ABBV) Pipeline Bolstered as FDA Approves Mavyret Label Expansion for Hepatitis C
AbbVie Inc. (NYSE:ABBV) received FDA approval for Mavyret expansion to treat Acute HCV, making it a top healthcare stock to buy. The drug's effectiveness in treating HCV shows promise amidst rising medical costs in the US.